DoMore Diagnostics welcomes Madeleine Xuyen Ho as our new Product Manager

OSLO – October 3, 2024 – DoMore Diagnostics, a leader in AI and deep-learning precision medicine in cancer, is pleased to announce the appointment of Madeleine Xuyen Ho as our new Product Manager.

Madeleine has an extensive background in the medical device and digital products industry with senior roles in Business Development, Product Strategy and Sales, most recently from the role as Business and Product Manager at Medistim ASA. Her background includes national and international product and customer lifecycle management across the Nordics, USA, EMEA and APAC. With a strong market and customer-focused mindset, Madeleine will play a key role in driving DoMore Diagnostics’ Histotype Px product portfolio to clinical implementation and commercial launch.  

CEO and Co-Founder Torbjørn Furuseth, MD, said: “We are thrilled to welcome Madeleine to our growing team! With her extensive background from the medical device industry, specialized clinical care settings and impressive commercial track-record, she will play a leading role in our efforts to strengthen our product development and market positioning as the company is preparing for commercial launch and progressing towards a more market-oriented phase. “

"I always have a strong belief in what I do, and with dedication and a strategic mindset I have enjoyed contributing to the commercial and clinical development of the companies I’ve joined as well as the therapeutic areas I have been working in. When I got the opportunity to become a part of the DoMore Diagnostics team, there was no hesitation. I cannot wait to start this exciting journey and help realize our shared goal to personalize treatment, change clinical practice and improve outcomes for cancer patients worldwide," added Madeleine Xuyen Ho.

About DoMore Diagnostics

DoMore Diagnostics uses artificial intelligence to make personalized treatment decisions simple and accessible for all cancer patients. Its unique digital biomarkers predict patient outcomes from routine tumor tissue slides and can be seamlessly integrated into pathologists’ existing workflow. The lead product Histotype Px® Colorectal is a CE-IVDD marked outcome prediction marker for stage II and III colorectal adenocarcinoma that informs the decision of whether to provide adjuvant chemotherapy following surgical resection of the tumor.

About Colorectal Cancer and Histotype Px® Colorectal

Colorectal cancer is the third most common and second most deadly cancer but has seen little innovation in diagnostics and treatment the last decades. Adjuvant chemotherapy (ACT) may be provided after primary surgery to prevent the disease from recurring, however overtreatment is prevalent with up to 85% of patients with stage II and stage III not benefitting from ACT and only suffering side effects.

Histotype Px® is an advanced deep learning algorithm that analyzes digital histology slides, separating patients into distinct Low, Intermediate and High-risk groups to guide ACT treatment decisions. Data previously published in The Lancet and The Lancet Oncology showed that the test can accurately predict survival outcomes in colorectal cancer patients. Histotype Px® Colorectal was developed to provide clinicians with valuable information to guide personalized treatment decisions and improve patient outcomes.

 

For more information about DoMore Diagnostics, please visit:

Website

LinkedIn

Contact:

Torbjørn Furuseth, MD

DoMore Diagnostics

torbjorn.furuseth@domorediagnostics.com

Previous
Previous

DoMore Diagnostics and Gustave Roussy Announce Clinical Research Collaboration

Next
Next

Colon cancer study to be presented at ESMO 2024 shows excellent performance of the digital pathology biomarker Histotype Px® Colorectal in combination with ctDNA in analysis of over 1000 patients